Medical Care Research and Review

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

The Diabetes Educator

Click here for free access to the SAGE eReference platform!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Phillips, K. A.
Right arrow Articles by Van Bebber, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Phillips, K. A.
Right arrow Articles by Van Bebber, S. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Medical Care Research and Review, Vol. 63, No. 3, 301-326 (2006)
DOI: 10.1177/1077558706287020

Regulatory Perspectives on Pharmacogenomics: A Review of the Literature on Key Issues Faced by the United States Food and Drug Administration

Kathryn A. Phillips

University of California, San Francisco, PhillipsK{at}pharmacy.ucsf.edu

Stephanie L. Van Bebber

University of California, San Francisco

Pharmacogenomics (PGx), the use of genetic information to individualize drug therapy, is an immediate and important application of the Human Genome Project. The advent of PGx presents challenges to the U.S. Food and Drug Administration (FDA) in pursuing its mandate of protecting public health and safety. The authors conducted a review of academic, industry, and government literature using a technology diffusion framework to identify issues faced by the FDA relevant to the application of PGx. Two hundred and ten articles were reviewed. Key issues were categorized as rationale and structure for PGx regulation, regulation of PGx-based testing technologies, regulation of applications in clinical settings, regulation of data, and regulation of product life cycles. This review identifies issues faced by the FDA with respect to PGx, which the FDA is addressing through several initiatives. It also illustrates the complex issues involved in developing, implementing, and adopting new technologies.

Key Words: regulation • pharmacogenomics • genetics • health technologies • government/industry relationships


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 aacredbookHome page
H. H Ezzeldin
Challenges in Pharmacogenomic Testing
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 471 - 476.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
V. L. Ellingrod and J. Moline
Incorporating Pharmacogenomics into Practice
Journal of Pharmacy Practice, June 1, 2007; 20(3): 277 - 282.
[Abstract] [PDF]